Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02196285
Other study ID # ASCLIN 002/2014
Secondary ID
Status Completed
Phase Phase 1
First received July 16, 2014
Last updated June 21, 2016
Start date September 2015
Est. completion date March 2016

Study information

Verified date June 2016
Source The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Contact n/a
Is FDA regulated No
Health authority Brazil: Agencia Nacional de Vigilância Sanitaria (ANVISA-MoH)
Study type Interventional

Clinical Trial Summary

Measles and rubella are highly contagious acute viral diseases. As per WHO, several evidences demonstrate the benefit for providing the universal access to vaccines containing measles and rubella antigens, mainly due to, respectively, mortality in children and malformations in fetuses. This is a Phase I, open study, non-controlled, to evaluate the safety, tolerability and imunogenicity of double viral vaccine anti-measles and rubella (MR), which is developed and produced at Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in human beings. 30 eligible volunteers, between 18-49 years old, will be vaccinated and monitored for local and systemic adverse events and titration of antibodies. The study will last 20 months in total.


Description:

This is a Phase I, open study, non-controlled, to evaluate the safety, tolerability and imunogenicity of double viral vaccine anti-measles and rubella (MR), which is developed and produced at Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in human beings. 30 eligible volunteers, between 18-49 years old, will be vaccinated and monitored for local and systemic adverse events and titration of antibodies. The study will last 20 months in total.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 2016
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria:

- Male

- Age between 18 and 49 years old;

- Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications);

- Willing to strictly follow the study protocol;

- Capacity for understanding and signing in the Informed Consent Form;

- To understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion;

- Intellectual level which allows to filling in the diaries for registering of symptoms at home;

- Willing to undergo to serological testing to HIV, HBV and HCV;

- Being in good health, with no significant medical history;

- Physical examination at screening period without clinically significant changes;

- Lab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision.

Exclusion Criteria:

- Serious adverse reaction to any vaccination, as respiratory difficulty, angioedema and anaphylaxis;

- Acute or chronic disease, as diabetes, heart disease, systemic arterial hypertension;

- Use of anti-allergic with antigen injections in a maximum timeline of 14 days before the vaccination;

- Use of immunoglobulin in the past 12 months before the study vaccination;

- Use of blood products within 12 months before the vaccination;

- Use of any vaccine type within 30 days before the vaccination of the study;

- Chronic use of any medication, except homeopathy, and trivial ones, as nasal physiologic solution and vitamins;

- Previous immunosuppressive or cytotoxic medication, in the last 6 months. Individuals who have made use of this kind of medication in non-immunosuppressant doses, as nasal corticosteroid for allergic rhinitis of topic corticosteroid for non-complicated dermatitis, for more than 14 days, are allowed to be included in the study.

- Use of any kind of medication under investigation within one year before the vaccination.

- Unstable asthma or which may have required urgent care, hospitalization or intubation within the last 2 years, or which requires use of oral or intravenous corticosteroid.

- Coagulopathies diagnosed by a physician or report of capillary fragility (ex: bruises or bleedings without justifiable cause;

- Convulsions, except the ones caused by fever, before 2 years old;

- Psychiatric disease which difficults the adherence to the protocol, such as psychosis, obsessive-compulsive disorders, bipolar disease under treatment, diseases which require treatment with lithium and suicidal ideas in the last 5 years from the inclusion;

- Active malignant (p.e. any kind of cancer) or treated disease, to which the individual may relapse during the study;

- Asplenia (absence of spleen or its removal);

- Positive HIV in the screening examination of history of any immunosuppressant disease;

- Positive serology for C hepatitis in the screening evaluation;

- Positive Antigen HBs in the screening evaluation;

- Alcoholism (CAGE criteria), used for detection of abusive drinkers or alcoholic, validated in the Brazilian population with sensibility of 88% and specificity of 83%, if two or more answers, among four possible, are afirmative(Mansur and Monteiro, 1983), or according to medical decision;

- Abuse of illicit drugs, according to medical decision;

- Acquired or congenital immunodeficiency;

- Allergy to the vaccine compounds, as egg, neomycin and gelatin.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Double viral (MR) vaccine
Measles and Rubella vaccine, as single arm

Locations

Country Name City State
Brazil Unidade de Ensaios Clínicos para Imunobiológicos Rio de Janeiro RJ

Sponsors (2)

Lead Sponsor Collaborator
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) Bill and Melinda Gates Foundation

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability analysis of the study vaccine To evaluate the occurrence of serious adverse events among the subjects who have received study vaccine. 9 months Yes
Secondary Imunogenicity analysis To evaluate imune response between post and pre-vaccination antibodies. 9 months No
See also
  Status Clinical Trial Phase
Completed NCT04183114 - Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Phase 2/Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00313950 - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Phase 4
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT01777529 - Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Phase 4
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT00109278 - A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) Phase 2
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT02880865 - Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Phase 4
Completed NCT01681992 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Phase 3
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT01702428 - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00388440 - Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Phase 4
Completed NCT03148990 - Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Phase 2/Phase 3